A$3.92 0.1 1.8%
Last Trade - 5:10am
| Market Cap | £1.36bn |
| Enterprise Value | £2.27bn |
| Revenue | £898.3m |
| Position in Universe | 175th / 1843 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1,580 | 1,642 | 1,659 | 1,705 | 1,562 | 1,585 | 1,848 | 1,814 | +0.06% | ||
| -12.0 | -9.0 | +163.8 | -72.6 | -25.7 | +27.4 | +69.2 | -10.8 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Healius Ltd, formerly Primary Health Care Limited is a medical center operator. The Company also operates as a provider of diagnostic imaging services; a provider of pathology services, and a provider of health technology. It provides a range of services and facilities to healthcare practitioners, and its medical center operations include the provision of day surgery and in vitro fertilization services by healthcare practitioners. Its segments include Medical Centres, Pathology, Imaging, Health Technology and Other. The Medical Centres division provides services and facilities to general practitioners, specialists and other healthcare providers, and includes Transport Health. The Pathology division provides pathology services. The Imaging division provides imaging and scanning services from standalone imaging sites and from within the consolidated entity's medical centers. The Health Technology division develops, sells and supports health-related software products.
| Last Annual | June 30th, 2020 |
| Last Interim | June 30th, 2020 |
| Incorporated | May 17, 1994 |
| Public Since | July 3, 1998 |
| No. of Shareholders: | 13,455 |
| No. of Employees: | 12,500 |
| Sector | Healthcare |
| Industry | Healthcare Providers & Services |
| Index | S&P/ASX All Ordinaries , S&P/ASX 200 , S&P/ASX 300 , ASX Small Ordinaries , |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 622,743,000 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | L 6 203 Pacific Hwy St Leonards, SYDNEY, 2065, Australia |
| Web | https://www.healius.com.au/ |
| Phone | +61 2 94329400 |
| Contact | () |
| Auditors | Ernst & Young |
As of 5:10am, shares in Healius are trading at A$3.92, giving the company a market capitalisation of £1.36bn. This share price information is delayed by 15 minutes.
Shares in Healius are currently trading at A$3.92 and the price has moved by 30.95% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Healius price has moved by 35.88% over the past year.
Of the analysts with advisory recommendations for Healius, there are there are currently 0 "buy" , 5 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Healius is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Healius is scheduled to issue upcoming financial results on the following dates:
The Healius dividend yield is 0.68% based on the trailing twelve month period.
Last year, Healius paid a total dividend of 0.03, and it currently has a trailing dividend yield of 0.68%. Looking ahead, Healius has not announced an ex-dividend date yet.
Healius has yet to annouce their ex-dividend date. The historic dividend yield on Healius shares is currently 0.68%.
To buy shares in Healius you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Healius are currently trading at A$3.92, giving the company a market capitalisation of £1.36bn.
Here are the trading details for Healius:
Based on an overall assessment of its quality, value and momentum, Healius is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Healius are currently priced at A$3.92. At that level they are trading at 3.12% discount to the analyst consensus target price of 0.00.
Analysts covering Healius currently have a consensus Earnings Per Share (EPS) forecast of 0.203 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Healius. Over the past six months, the relative strength of its shares against the market has been 9.83%. At the current price of A$3.92, shares in Healius are trading at 20.25% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Healius PE ratio based on its reported earnings over the past 12 months is 32.08. The shares are currently trading at A$3.92.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Healius's management team is headed by:
Here are the top five shareholders of Healius based on the size of their shareholding:
